Abstract:Background: Aspirin is a frequently prescribed drug for primary and secondary prevention of myocardial infarction, stroke and cardiovascular death. However, aspirin resistance may affect up to 45% of the population. Little is known on the role of genetic factors that contribute to resistance or augmented response to aspirin in different human populations. Methods: In a large sample of nonsmoker, medication-free healthy volunteers from mainland China (n = 323; age: 22.1 +/- 2.0 years) (mean standard deviation), we determined the frequency of polymorphisms in cyclooxygenase 1 (COX1) (A-842G and C50T), glycoprotein IIIa (GPIIIa) (PLA1/A2) and purinergic receptor P2Y (P2Y1) (C893T and A1622G) genes. These candidate genes were chosen on the basis of their impact on platelet physiology and aspirin mode of action. A four panel P2Y1 genotype-stratified sample of healthy volunteers (n = 24 in total), identified from the large study sample above, prospectively received a 100 mg daily oral dose of aspirin for 7 days. We measured changes in platelet aggregation before and after aspirin treatment. As a comparison reference group, 6 out of 24 subjects in the prospective aspirin trial had the P2Y1 CT893/AG1622 genotype that displays a low frequency (< 7%) in the Chinese population. Results: COX1 A-842G, C50T and GPIIIa PLAVA2 genetic polymorphisms were not observed in our sample from mainland China. Allele frequencies of P2Y1 893T and 1622G were 3.5 and 30.6%, respectively. The heterozygosity for the P2YI A1622G polymorphism observed in the present study was different to Caucasians; Chinese displayed a higher allele frequency for the 1622G allele. After aspirin treatment, the net decrease in arachiclonic acid-induced platelet aggregation was significantly larger in the P2Y1 CT893/AG1622 genotype panel (83.4 +/- 3.7%, net reduction by aspirin expressed as percentage of baseline) compared with CC893/GG1622 (68.2 +/- 13.5%), CC893/AG1622 (68.9 +/- 9.6%) and CC893/AA1622 (65.1 +/- 9.1 %) genotypic groups (p = 0.012, 0.025 and 0.004, respectively; statistical power = 77%). There was no significant difference in antiplatelet effect of aspirin among the CC893/GG1622, CC893/AG1622 and CC893/AA1622 genotypes (p > 0.05). Conclusions: The COX1 A-842G, C50T and GPIIIa PLAVA2 polymorphisms are rare in Chinese. In contrast to previous studies in Caucasian populations, these candidate functional polymorphisms are unlikely to be significant contributors to aspirin pharmacodynamics in Chinese persons. Importantly, the presence of the P2YI 893CC genotype appears to confer an attenuated antiplatelet effect during aspirin treatment in healthy Chinese volunteers. These data collectively underscore the importance of population-to-population variability in clinical pharmacogenetics research and provide a basis for further long-term studies of aspirin response and P2Y1 genetic variation in patients with cardiovascular risk.

Relationship Between Single Nucleotide Polymorphisms in Promoter Region of Cyclooxygenase-2 Gene and Aspirin Resistance in the Elderly

Common Single Nucleotide Polymorphisms In Cyclooxygenase-2 And Risk Of Severe Chronic Periodontitis In A Chinese Population

[Correlation analysis of aspirin resistance and cycloxygenase-1 haplotype in old Chinese patients with cardio-cerebrovascular diseases].

The correlation between therapeutic efficacy of aspirin and cyclooxygenase

The risk of COX-2-1195GA polymorphism in type 2 diabetes with periodontitis

Aspirin Resistance in the Elder Cardio-Cerebral-Vascular Diseases Patients

A Study on the Correlation Between Aspirin Resistance and Gene Polymorphisms

Association between cyclooxygenase-1/-2 genetic polymorphisms and aspirin resistance in ischemic stroke patients

Frequency of genetic polymorphisms of COX1, GPIIIa and P2Y1 in a Chinese population and association with attenuated response to aspirin.

Changes of Platelet Function after Antiplatelet Therapy and Single Nucleotide Polymorphism of COX-1 and COX-2 in Elderly Patients

The Association of Four Common Polymorphisms from Four Candidate Genes (COX-1, COX-2, ITGA2B, ITGA2) with Aspirin Insensitivity: a Meta-Analysis.

A study of COX-2 polymorphisms in patients with Alzheimer’s disease

Impacts of COX-1 Gene Polymorphisms on Vascular Outcomes in Patients with Ischemic Stroke and Treated with Aspirin

Gene Polymorphisms of Insulin Secretion Signaling Pathway Associated with Clopidogrel Resistance in Han Chinese Population.

Association between cyclooxygenase-2 single nucleotide polymorphism and genetic susceptibility of colorectal adenoma

IDENTIFICATION OF ASPIRIN RESPONSE RELATED GENE PROFILES IN THE ELDERLY POPULATION WITH CORONARY ARTERY DISEASE

[Association Between Single Nucleotide Polymorphisms in the Promoter of Cyclooxygenase COX-2 Gene and Hereditary Susceptibility to Pancreatic Cancer].

Cyclooxygenase-2 Gene Polymorphisms and Susceptibility to Hepatocellular Carcinoma

Genetic factors related to aspirin resistance using the Multiplate® device in Hong Kong Chinese patients with stable coronary heart disease

Prognostic Value of Cyclooxygenase-2 Gene Polymorphisms in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Platinum-Based Chemotherapy.

Relationship between cyclooxygenase 2 gene polymorphism and clinical outcome in atherosclerosis ischemic stroke patients